MA49508A - Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques - Google Patents

Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques

Info

Publication number
MA49508A
MA49508A MA049508A MA49508A MA49508A MA 49508 A MA49508 A MA 49508A MA 049508 A MA049508 A MA 049508A MA 49508 A MA49508 A MA 49508A MA 49508 A MA49508 A MA 49508A
Authority
MA
Morocco
Prior art keywords
sarcomera
activators
cardiac
processes
heart failure
Prior art date
Application number
MA049508A
Other languages
English (en)
Other versions
MA49508B1 (fr
Inventor
Malik Fady
Narimon Honarpour
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of MA49508A publication Critical patent/MA49508A/fr
Publication of MA49508B1 publication Critical patent/MA49508B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA49508A 2017-06-30 2018-06-29 Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques MA49508B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527983P 2017-06-30 2017-06-30
EP18745732.0A EP3645002B1 (fr) 2017-06-30 2018-06-29 Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
PCT/US2018/040181 WO2019006235A1 (fr) 2017-06-30 2018-06-29 Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques

Publications (2)

Publication Number Publication Date
MA49508A true MA49508A (fr) 2020-05-06
MA49508B1 MA49508B1 (fr) 2024-12-31

Family

ID=63013097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49508A MA49508B1 (fr) 2017-06-30 2018-06-29 Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques

Country Status (22)

Country Link
US (4) US11576910B2 (fr)
EP (2) EP3645002B1 (fr)
JP (3) JP2020526483A (fr)
CN (1) CN110996953A (fr)
AU (2) AU2018290983B2 (fr)
BR (1) BR112019028046A2 (fr)
CA (1) CA3068588A1 (fr)
DK (1) DK3645002T3 (fr)
ES (1) ES3008457T3 (fr)
FI (1) FI3645002T3 (fr)
HR (1) HRP20241729T1 (fr)
HU (1) HUE069805T2 (fr)
LT (1) LT3645002T (fr)
MA (1) MA49508B1 (fr)
MD (1) MD3645002T2 (fr)
MX (2) MX2020000190A (fr)
PL (1) PL3645002T3 (fr)
PT (1) PT3645002T (fr)
RS (1) RS66581B1 (fr)
SI (1) SI3645002T1 (fr)
SM (1) SMT202500067T1 (fr)
WO (1) WO2019006235A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료
US20230090391A1 (en) * 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
WO2021257456A1 (fr) * 2020-06-15 2021-12-23 MyoKardia, Inc. Traitement d'un dysfonctionnement atrial
DK4243825T3 (da) * 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
US20250161298A1 (en) * 2022-02-22 2025-05-22 Yale University Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth
JP2025534288A (ja) 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
WO2024081611A1 (fr) * 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
EP4688756A1 (fr) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Composés de quinazoline dione et leurs utilisations
WO2024206339A1 (fr) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Composés d'amide de quinolinone et leurs utilisations
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (fr) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil destiné à être utilisé dans le traitement de l'insuffisance cardiaque par activation d'un sarcomere cardiaque

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
EP1053752A1 (fr) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a liberation controlee
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
AU2003279842A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
WO2008130158A1 (fr) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd Composition de microsphères biodégradables à libération contrôlée d'un peptide régulateur du glucose et formule associée
US9895308B2 (en) * 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
SG11201507258PA (en) 2013-03-14 2015-10-29 Amgen Inc Heterocyclic compounds and their uses
EP3250557B1 (fr) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-méthylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
CA3052625A1 (fr) 2017-02-06 2018-08-09 Acceleron Pharma Inc. Compositions et methodes de traitement d'une insuffisance cardiaque
AU2018294254C1 (en) 2017-06-30 2022-10-13 Amgen Inc. Synthesis of omecamtiv mecarbil
DK3645002T3 (da) 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
EP3820851A1 (fr) 2018-07-12 2021-05-19 Assia Chemical Industries Ltd Formes à l'état solide d'omecamtiv mecarbil et d'omecamtiv mecarbil dihcl
FI3599243T3 (fi) 2018-07-26 2023-06-22 Cvie Therapeutics Ltd 17beeta-heterosyklyylidigitaliksen kaltaisia yhdisteitä sydämen vajaatoiminnan hoitoon
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (fr) 2018-12-18 2020-06-25 Amgen Inc. Procédé de réduction de composés nitro aromatiques
MX2021010483A (es) 2019-03-05 2021-10-01 Windtree Therapeutics Inc Formulacion intravenosa que contiene istaroxima para el tratamiento de insuficiencia cardiaca aguda (ahf).
WO2021053175A1 (fr) 2019-09-19 2021-03-25 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
EP4031541A1 (fr) 2019-09-19 2022-07-27 Synthon B.V. Sels d'omecamtiv mecarbil et formes solides de ceux-ci
EP4041710A1 (fr) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Nouveaux procédés destinés à la préparation de l'omécamtiv mécarbil
WO2021070123A1 (fr) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Formes solides de dichlorhydrate d'omecamtiv mecarbil et procédés associés
EP4054588A4 (fr) 2019-11-10 2023-12-13 MyoKardia, Inc. Méthodes de traitement comprenant un modulateur de myosine
GB201918853D0 (en) 2019-12-19 2020-02-05 Lund Lars H Methods of treatment
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
US20230090391A1 (en) 2020-02-10 2023-03-23 Amgen Inc. Omecamtiv mecarbil tablet
DK4243825T3 (da) 2020-11-12 2025-12-01 Amgen Inc Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper
IL305751A (en) 2021-03-10 2023-11-01 Amgen Inc SYNTHESIS OF OMECAMTIV MECARBIL
WO2023205291A2 (fr) 2022-04-21 2023-10-26 The Board Of Regents Of The University Of Oklahoma Ciblage de tissu myocardique pour l'administration d'agents thérapeutiques et d'imagerie
WO2024081611A1 (fr) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Méthodes de traitement de l'insuffisance cardiaque par administration d'activateurs de sarcomère cardiaque
US11986474B1 (en) * 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
EP4512470A3 (fr) 2025-04-23
US11576910B2 (en) 2023-02-14
HUE069805T2 (hu) 2025-04-28
MX2020000190A (es) 2020-07-22
EP3645002A1 (fr) 2020-05-06
SMT202500067T1 (it) 2025-03-12
CA3068588A1 (fr) 2019-01-03
EP3645002B1 (fr) 2024-10-30
US20250255862A1 (en) 2025-08-14
US20200155547A1 (en) 2020-05-21
AU2024200991B2 (en) 2025-04-10
AU2024200991A1 (en) 2024-03-07
US11931358B2 (en) 2024-03-19
AU2018290983A1 (en) 2020-01-23
BR112019028046A2 (pt) 2020-07-07
RS66581B1 (sr) 2025-04-30
PT3645002T (pt) 2025-01-24
AU2018290983B2 (en) 2023-11-23
WO2019006235A1 (fr) 2019-01-03
MA49508B1 (fr) 2024-12-31
HRP20241729T1 (hr) 2025-03-14
MX2022015115A (es) 2023-01-18
PL3645002T3 (pl) 2025-03-24
JP2025165979A (ja) 2025-11-05
FI3645002T3 (fi) 2025-01-29
JP2020526483A (ja) 2020-08-31
MD3645002T2 (ro) 2025-04-30
DK3645002T3 (da) 2024-12-16
ES3008457T3 (en) 2025-03-24
CN110996953A (zh) 2020-04-10
US12295952B2 (en) 2025-05-13
EP4512470A2 (fr) 2025-02-26
LT3645002T (lt) 2025-02-10
SI3645002T1 (sl) 2025-03-31
JP2023088944A (ja) 2023-06-27
US20230149394A1 (en) 2023-05-18
US20230355615A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MA49508A (fr) Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques
ZA202006636B (en) Use of sublingual dexmedetomidine for the treatment of agitation
MA50056A (fr) Procédés de traitement de tumeur
EP3773256A4 (fr) Dispositif d'exclusion d'appendice auriculaire
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3426250A4 (fr) Procédés de traitement
PH12017502107A1 (en) Triazole agonists of the apj receptor
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3601536A4 (fr) Procédés de traitement
FI4327866T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitoon
MA45192A (fr) Traitement d'association
DK3784103T3 (da) Gulvbehandlingsmaskine
BR112018005499A2 (pt) métodos de tratamento de pressão intraocular com ativadores de tie-2.
MA55515A (fr) Procédés de traitement de la dystrophie musculaire avec casimersen
EP3303639A4 (fr) Procédés intégrés de traitement d'une matière lignocellulosique
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
EP3619170A4 (fr) Procédé de traitement de l'eau
EP3615502A4 (fr) Composés et procédés thérapeutiques
TR201907044T4 (tr) Yeni bileşikler.
EP3402803A4 (fr) Procédés de traitement de l'ostéonécrose avec des composés de llp2a-bisphosphonate
IL280243A (en) Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure
HUE058867T2 (hu) Javított vegyület szívelégtelenség kezelésére
MA42611A (fr) Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines
PL3713883T3 (pl) System do biologicznego uzdatniania wody
EP3294930A4 (fr) Cuve d'électrolyse comprenant des éléments de renforcement